Vivelle-Dot News
Noven to Present at Raymond James Institutional Investors Conference - Business Wire (press release)
Noven’s leading transdermal products utilize its proprietary DOT Matrix ® drug delivery technology and include Vivelle-Dot ® (estradiol transdermal system), ...
Noven Receives FDA Warning Letter Related to Mid-2007 Facility ... - Genetic Engineering News (press release)
Its commercialized transdermal products include Vivelle-Dot(R) (estradiol transdermal system), the most prescribed estrogen patch in the US, ...
Noven's chief executive retires - Trading Markets (press release)
... Novogyne Pharmaceuticals, which has become a market leader in patches for post-menopausal female hormone treatments, such as the Vivelle-Dot patch. ...
CEO of drug-maker Noven retires - MiamiHerald.com
all 316 news articles
Noven Announces Changes to Board of Directors and Senior Management - WELT ONLINE
Its commercialized transdermal products include Vivelle-Dot® (estradiol transdermal system), the most prescribed estrogen patch in the US, and Daytrana™ ...
Noven Announces FDA Tentative Approval of Stavzor(TM) Valproic ... - FOX News
Its commercialized transdermal products include Vivelle-Dot(R) (estradiol transdermal system), the most prescribed estrogen patch in the US, ...
Noven Appoints Michael D. Price Chief Financial Officer - PR-Inside.com (Pressemitteilung)
Its commercialized transdermal products include Vivelle-Dot(R) (estradiol transdermal system), the most prescribed estrogen patch in the US, ...
Noven Pharmaceuticals 3Q earnings top expectations, revenue misses - Hemscott
... million associated with sales of jds's Pexeva and Lithobid products, higher sales of Noven's Vivelle-Dot estrogen patch and higher license revenues. ...
WallStreetStockReview.com: The Los Chorros Mine Update - Trading Markets (press release)
Its commercialized transdermal products include Vivelle-Dot (estradiol transdermal system), the most prescribed estrogen patch in the US, and Daytrana ...
Noven Pharmaceuticals 3Q earnings top expectations, revenue misses - CNNMoney.com
... million associated with sales of JDS's Pexeva and Lithobid products, higher sales of Noven's Vivelle-Dot estrogen patch and higher license revenues. ...
Vivelle-Dot RSS Feed